Stock’s Earning Overview for Karyopharm Therapeutics Inc.(NASDAQ:KPTI): Cardlytics, Inc.(NASDAQ:CDLX)

0
4

Karyopharm Therapeutics Inc. (KPTI) will report its next earnings on Nov 05 BMO. The company reported the earnings of $-0.71/Share in the last quarter where the estimated EPS by analysts was $-0.98/share. The difference between the expected and actual EPS was $0.27/share, which represents an Earnings surprise of 27.6%.

Many analysts are providing their Estimated Earnings analysis for Karyopharm Therapeutics Inc. and for the current quarter 8 analysts have projected that the stock could give an Average Earnings estimate of $-0.84/share. These analysts have also projected a Low Estimate of $-0.88/share and a High Estimate of $-0.74/share.

In case of Revenue Estimates, 8 analysts have provided their consensus Average Revenue Estimates for Karyopharm Therapeutics Inc. as 1.8 Million. According to these analysts, the Low Revenue Estimate for Karyopharm Therapeutics Inc. is 520 Million and the High Revenue Estimate is 4.3 Million. The company had Year Ago Sales of 239 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for KPTI to be -25.3%. They are projecting Next Quarter growth of 12.5%. For the next 5 years, Karyopharm Therapeutics Inc. is expecting Growth of 31.59% per annum, whereas in the past 5 years the growth was -9.87% per annum.

Some buy side analysts are also providing their Analysis on Karyopharm Therapeutics Inc., where 3 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Karyopharm Therapeutics Inc. might touch $32 high while the Average Price Target and Low price Target is $20.33 and $15 respectively.

Karyopharm Therapeutics Inc. closed its last trading session at $9.91 with the loss of -0.91%. The Market Capitalization of the company stands at 613.55 Million. The Company has 52-week high of $18.03 and 52-week low of $3.92. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -3.17% where SMA50 and SMA200 are 5.55% and 32.97% respectively. The Company Touched its 52-Week High on 10/01/18 and 52-Week Low on 03/01/19.

The Relative Volume of the company is 0.56 and Average Volume (3 months) is 2.73 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -79.5%. The Return on Equity (ROE) value stands at -154.7%. While it’s Return on Investment (ROI) value is -62.9%.

While looking at the Stock’s Performance, Karyopharm Therapeutics Inc. currently shows a Weekly Performance of -8.48%, where Monthly Performance is 10.34%, Quarterly performance is 63.94%, 6 Months performance is 68.15% and yearly performance percentage is -42.81%. Year to Date performance value (YTD perf) value is 4.8%. The Stock currently has a Weekly Volatility of 6.52% and Monthly Volatility of 6.67%.

Cardlytics, Inc. (CDLX) will report its next earnings on Nov 07 BMO. The company reported the earnings of $-0.12/Share in the last quarter where the estimated EPS by analysts was $-0.22/share. The difference between the expected and actual EPS was $0.1/share, which represents an Earnings surprise of 45.5%.

Many analysts are providing their Estimated Earnings analysis for Cardlytics, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.15/share. These analysts have also projected a Low Estimate of $-0.24/share and a High Estimate of $-0.1/share.

These analysts also forecasted Growth Estimates for the Current Quarter for CDLX to be -6.7%. They are projecting Next Quarter growth of -150%. For the next 5 years, Cardlytics, Inc. is expecting Growth of 76.21% per annum, whereas in the past 5 years the growth was 15.07% per annum.

Some buy side analysts are also providing their Analysis on Cardlytics, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

Cardlytics, Inc. closed its last trading session at $33.27 with the gain of 0.39%. The Market Capitalization of the company stands at 822.64 Million. The Company has 52-week high of $39.62 and 52-week low of $9.80. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -6.56% where SMA50 and SMA200 are 1.66% and 51.73% respectively. The Company Touched its 52-Week High on 09/09/19 and 52-Week Low on 12/31/18.

The Relative Volume of the company is 1.28 and Average Volume (3 months) is 465.61 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -22.5%. The Return on Equity (ROE) value stands at -66.5%. While it’s Return on Investment (ROI) value is -42.4%.

While looking at the Stock’s Performance, Cardlytics, Inc. currently shows a Weekly Performance of -7.48%, where Monthly Performance is -9.53%, Quarterly performance is 28.56%, 6 Months performance is 101.93% and yearly performance percentage is 33.28%. Year to Date performance value (YTD perf) value is 208.4%. The Stock currently has a Weekly Volatility of 6.16% and Monthly Volatility of 5.72%.

SHARE